INDP (Indaptus Therapeutics) Forward P/E Multiple
The forward P/E NTM of Indaptus Therapeutics (INDP) reflects the valuation dynamics relative to expected earnings, where the current status is 0.00. Indaptus Therapeutics is developing bacterial immuno-oncology, monetizing patents through royalties from pharma behemoths. The business currently lacks stable cash flow, remaining dependent on clinical success. High barriers to entry create stringent filters due to synthesis complexity and FDA requirements.
Analytical breakdowns for Indaptus Therapeutics
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Indaptus Therapeutics|INDP - Long-Term Debt to Capital|Short-Term Debt to Equity Indaptus Therapeutics|INDP - Company Aggregate Debt|Debts to Book Capitalization Indaptus Therapeutics Inc|INDP - Long-Term Debt|Company Short-Term Debts Indaptus Therapeutics|Quick Liquidity indaptusrx.com
- company profitability and valuation multiples indicators:
INDP - Company Profit|Projected Future Earnings Indaptus Therapeutics|INDP - Price to Earnings Multiple|Forward P/E Multiple Indaptus|INDP - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Indaptus Therapeutics Inc|INDP - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Indaptus Therapeutics|INDP - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months indaptusrx.com|INDP - Earnings growth in current year|Net earnings per share growth forecast for next year Indaptus Therapeutics
Summary company analytics:Indaptus Therapeutics, Inc.
The lack of revenue and high clinical trial costs at Indaptus Therapeutics (INDP) create extreme negative operating leverage, complicating a classic valuation. The company's forward P/E ratio compares current market capitalization with expected earnings, allowing investors to determine the degree of optimism priced in regarding future drug commercialization and filter out market noise.
Competitors of Indaptus Therapeutics (INDP)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings ADPT|Forward P/E Multiple Celldex Corp|Future Price to Earnings Aurinia Pharmaceuticals (AUPH)|biocryst.com - Price to Future Earnings Ratio|Forward P/E Multiple VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Projected Price to Earnings Ratio|Pharvaris Corp - Forward P/E Multiple|Market Cap to Projected Earnings AbCellera Biologics ABCL|Tourmaline Bio, Inc. (TRML) - Future Price to Earnings|Price to Future Earnings Ratio PGEN|PHAR (Pharming Group) - Forward P/E Multiple|Price to Future Earnings Ratio NKTR (Nektar Therapeutics Inc)|Forward P/E Multiple UPB|Forward P/E Multiple Zenas Corp (ZBIO)|Future Price to Earnings Immunome, Inc. IMNM|GOSS (gossamerbio.com) - Price to Expected Earnings Ratio|KALV: Projected Price to Earnings|Septerna, Inc. - Market Cap to Future Earnings Ratio|PVLA (Pieris Pharmaceuticals Inc) - Projected Price to Earnings|Savara Pharma (SVRA) - Forward P/E Multiple|Future Price to Earnings Rigel Pharmaceuticals|anaptysbio.com (ANAB) - Market Cap to Projected Earnings|Projected Price to Earnings ATXS (Astria Therapeutics, Inc.)|ENGN (enGene Holdings Inc) - Future Price to Earnings Multiple|RAPT Therapeutics, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio JBIO (Aerovate Therapeutics, Inc.)|Aclaris Therapeutics - Forward P/E Multiple|Future Price to Earnings Multiple KYTX (kyvernatx.com)|TLSA: Forward P/E Multiple|Projected Price to Earnings Ratio Cabaletta Bio Inc. (CABA)|Future Price to Earnings Ventyx Bio|THTX: Future Price to Earnings Multiple|Forward P/E Multiple AVTX|Forward P/E Multiple eledon.com (ELDN)|Future Price to Earnings Agenus Inc. AGEN|CLYM (Climb Bio Inc.) - Price to Expected Earnings Ratio|Zura Bio Limited - Forward P/E Multiple|Projected Price to Earnings Ratio aTyr Pharmaceuticals|ADAG (adagene.com) - Projected Price to Earnings|Ikena Oncology (IMA) - Forward P/E Multiple|Projected Price to Earnings STTK|EQ (Equillium Bio) - Market Cap to Future Earnings Ratio|Forward P/E Multiple CNTB|Market Cap to Projected Earnings immunic-therapeutics.com|Forward P/E Multiple ATRA (Atara Bio)|IFRX - Projected Price to Earnings|XFOR - Future Price to Earnings|Market Cap to Projected Earnings Adicet Bio ACET|CELU: Forward P/E Multiple|INMB - Market Cap to Projected Earnings|Future Price to Earnings Barinthus Biotherapeutics|Price to Future Earnings Ratio KZR (kezarlifesciences.com)|Forward P/E Multiple SABS|Akari Therapeutics PLC - Price to Future Earnings Ratio|Future Price to Earnings Enlivex Therapeutics Ltd. ENLV|QTTB (Q32 Bio Inc) - Price to Expected Earnings Ratio|GOVX - Future Price to Earnings|Price to Expected Earnings Ratio EDSA|IBIO: Forward P/E Multiple|Carisma Therapeutics Inc. - Future Price to Earnings Multiple|XTLB (XTL Biopharmaceuticals, Ltd.) - Forward P/E Multiple|Forward P/E Multiple Bolt Bio|Future Price to Earnings HCW Biologics Inc. (HCWB)|APVO (aptevotherapeutics.com) - Future Price to Earnings Multiple|Future Price to Earnings AIM ImmunoTech AIM|ADTX - Projected Price to Earnings|GRI Bio Corp - Forward P/E Multiple|XRTX - Forward P/E Multiple|HIND (Vyome Holdings Inc) - Projected Price to Earnings|revbiosciences.com - Future Price to Earnings Multiple|SCNI (Scinai Immunotherapeutics Ltd.) - Forward P/E Multiple|CalciMedica Corp (CALI) - Market Cap to Projected Earnings|Future Price to Earnings Affimed (AFMD)|Projected Price to Earnings allakos.com ALLK|Future Price to Earnings HOOKIPA Pharma HOOK|IGMS - Projected Price to Earnings|ITOS: Projected Price to Earnings|OCEA - Forward P/E Multiple|TC BioPharm (Holdings) PLC (TCBP) - Future Price to Earnings|Price to Future Earnings Ratio THRD
